BioDaVinci is making regenerative medicine mainstream by leveraging its unique, scalable technology. The company’s first product is a drug to repair damaged gut barrier, with anticipated peak sales of $5B per year. The company’s CEO and co-founder was Harvard Medical School’s first regenerative medicine PhD and built the world’s first gut-on-a-chip from stem cells at MIT.